User menu

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Bibliographic reference Sonneveld, Pieter ; Hajek, Roman ; Nagler, Arnon ; Spencer, Andrew ; Bladé, Joan ; et. al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.. In: Cancer, Vol. 112, no.7, p. 1529-37 (2008)
Permanent URL http://hdl.handle.net/2078.1/123483
  1. American Cancer Society. Cancer Facts and Figures, 2006. Atlanta, Ga: American Cancer Society, Inc.; 2006.
  2. ,,. GLOBOCAN 2002: Cancer incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.
  3. Durie, Clin Lymphoma Myeloma., 6, 181 (2005)
  4. Kyle, Mayo Clin Proc., 78, 21 (2003)
  5. Rajkumar, Leukemia., 17, 775 (2003)
  6. Rajkumar, Proc Am Soc Clin Oncol., 23, 593s (2005)
  7. Rajkumar, J Clin Oncol., 24, 431 (2006)
  8. Safra, Oncologist., 8, 17 (2003)
  9. Baz, Blood., 106, 719a (2005)
  10. Padmanabhan, Haematologica., 91, 277 (2006)
  11. Hussein, Mayo Clin Proc., 81, 889 (2006)
  12. Hussein, Semin Hematol., 42, s22 (2005)
  13. THALOMID (thalidomide) Capsules [prescribing information]. Summit, NJ: Celgene Corporation; 2007.
  14. Wang, Blood (ASH Annual Meeting Abstracts)., 108 (2006)
  15. Wang, Proc Am Soc Clin Oncol., 24, 427s (2006)
  16. Orlowski, J Clin Oncol., 25, 3892 (2007)
  17. Musto, Leuk Res., 28, 325 (2004)
  18. Blade, Br J Haematol., 102, 1115 (1998)
  19. Richardson, Blood., 100, 3063 (2002)